Welcome to our dedicated page for Merck & Co. SEC filings (Ticker: MRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Merck & Co., Inc. filings document the regulatory record of a New Jersey pharmaceutical issuer with common stock and multiple debt securities registered on the New York Stock Exchange. The company's disclosures cover operating and financial results, clinical and regulatory matters, material agreements, governance matters and capital-structure changes.
Merck's SEC record includes Form 8-K material-event reports, definitive proxy materials and debt-financing disclosures. Recent filings describe underwritten public offerings of notes, registered securities, shareholder voting matters, board and executive-governance information, and other events tied to the company's pharmaceutical, vaccine and animal health businesses.
Merck & Co., Inc. (MRK) reported an initial statement of beneficial ownership for executive vice president and chief information and digital officer Gaurav K. Gupta. He holds 19,443 Restricted Stock Units, each representing a contingent right to receive one share of Merck common stock, vesting in three equal installments on August 7, 2027, 2028, and 2029. He also directly holds 750 shares of Merck common stock.
Merck & Co., Inc. executive Chirfi Guindo, EVP, Access, Policy & Comms, reported selling 10,000 shares of common stock on August 13, 2026 in a sale classified as an open market or private transaction at $135.00 per share. Following this transaction, Guindo directly holds 36,613.127 shares of Merck common stock.
CHIRFI GUINDO filed a notice covering planned sales of Common Stock of issuer MRK. The filing lists 10,000 shares of Common Stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $1,350,000.00 and a planned sale date of 08/13/2026 on the NYSE. These shares relate to restricted stock vesting under a registered plan dated 01/27/2025. The filing also reports that, during the past three months, GUINDO sold 15,000 shares of Common Stock on 08/06/2026 for an aggregate value of $1,965,000.00.
Merck & Co., Inc. EVP and General Counsel Jennifer Zachary exercised stock options for 41,494 shares at an exercise price of $117.89 and 13,433 shares at $84.71, then sold 80,315 common shares on 2026-08-12 at a weighted average price of $133.4557 per share, within a price range of $133.03 to $133.50. The options referenced in the footnotes vested or will vest in equal annual installments. The transactions are not reported as made under a Rule 10b5-1 trading plan.
Richard Robert DeLuca Jr. filed a Form 144 relating to sales of common stock of issuer MRK, using Morgan Stanley Smith Barney LLC Executive Financial Services as broker. Disclosed prior 3‑month sales include 6,050 shares on 08/06/2026 for $788,772.63, 20,784 shares on 08/10/2026 for $2,710,950.65, and 12,837 shares on 08/11/2026 for $1,691,426.23. Earlier entries list restricted stock vesting under a registered plan.
A holder of MRK common stock filed to sell up to 80,315 shares through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE around 08/12/2026, with an aggregate market value of $10,718,494.55. These shares were obtained via option exercises and restricted stock vesting under registered compensation plans between 2023 and 2026.
Merck & Co., Inc. executive Richard R. DeLuca, EVP & President, Merck Animal Health, reported selling a total of 45,320 shares of Merck common stock in open-market or private transactions on August 10–12, 2026weighted averages based on multiple trades within price ranges from $130.0000 to $132.6514, as detailed in footnotes. The Rule 10b5‑1 trading-plan checkbox was not selected.
An affiliate of an MRK insider filed to potentially sell 12,837 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an approximate sale date of 08/11/2026 and total shares outstanding of 2,467,171,638. The filer previously acquired shares through restricted stock vesting and reported past 3‑month sales of 20,784 and 6,050 shares of common stock.
MRK executive Richard Robert DeLuca Jr. filed a notice to sell up to 20,784 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate value of $2,710,950.65, to be sold on or after 08/10/2026 on the NYSE.
The filing also reports a prior sale of 6,050 common shares on 08/06/2026 for total proceeds of $788,772.63.
Merck & Co., Inc. executive Richard R. DeLuca, EVP & President, Merck Animal Health, reported selling a total of 6,050 shares of Merck common stock on 2026-08-06 in three open-market transactions. The reported per-share prices are weighted averages, with actual trade prices within disclosed ranges around $130–$131 per share.